Aveo finally earns approval for kidney cancer drug

More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news